Similar articles

• Cardiovascular magnetic resonance in the evaluation of hypertrophic and infiltrative cardiomyopathies.

  O'Hanlon R, Pennell DJ. O'Hanlon R, et al. Heart Fail Clin. 2009 Jul;5(3):369-87, vi. doi: 10.1016/j.hfc.2009.02.003. Heart Fail Clin. 2009. PMID: 19564014 Review.
• Role of cardiac magnetic resonance imaging in assessment of nonischemic cardiomyopathies.

  Shehata ML, Turkbey EB, Vogel-Claussen J, Bluemke DA. Shehata ML, et al. Top Magn Reson Imaging. 2008 Feb;19(1):43-57. doi: 10.1097/RMR.0b013e31816fcb22. Top Magn Reson Imaging. 2008. PMID: 18690160 Review.
• [Patterns of delayed-enhancement in MRI of ischemic and non-ischemic cardiomyopathies].

  Stork A, Müllerleile K, Bansmann PM, Koops A, Meinertz T, Adam G, Lund GK. Stork A, et al. Rofo. 2007 Jan;179(1):21-30. doi: 10.1055/s-2006-927204. Rofo. 2007. PMID: 17203440 Review. German.
• The role of cardiovascular magnetic resonance in the diagnosis and management of cardiomyopathies.

  Masci PG, Dymarkowski S, Bogaert J. Masci PG, et al. J Cardiovasc Med (Hagerstown). 2008 May;9(5):435-49. doi: 10.2459/JCM.0b013e32827ab49f. J Cardiovasc Med (Hagerstown). 2008. PMID: 18403995 Review.
• Risk stratification for therapeutic management and prognosis.

  Coelho-Filho OR, Nallamshetty L, Kwong RY. Coelho-Filho OR, et al. Heart Fail Clin. 2009 Jul;5(3):437-55, vii. doi: 10.1016/j.hfc.2009.02.010. Heart Fail Clin. 2009. PMID: 19564018 Review.